Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 29:9:649053.
doi: 10.3389/fped.2021.649053. eCollection 2021.

Clinical Characterization of Anti-GQ1b Antibody Syndrome in Childhood

Lianhong Cai  1 , Zhanqi Hu  2 , Jianxiang Liao  2 , Siqi Hong  1 , Lingyu Kong  2 , Li Chen  2 , Yetao Luo  3 , Tingsong Li  1 , Li Jiang  1
Affiliations

Clinical Characterization of Anti-GQ1b Antibody Syndrome in Childhood

Lianhong Cai et al. Front Pediatr. .

Abstract

Objective: To delineate the comprehensive clinical features of anti-GQ1b antibody syndrome in childhood. Methods: The clinical data of children diagnosed with anti-GQ1b antibody syndrome at two Chinese tertiary pediatric neurology centers were collected and analyzed. We also conducted a systematic literature review on anti-GQ1b antibody syndrome in children. Results: This study included 78 children with anti-GQ1b antibody syndrome, consisting of 12 previously unreported cases from the two Chinese centers. The median onset age was 10 years (range, 2-18 years). The most common phenotype was acute ophthalmoparesis (32%), followed by classic Miller Fisher syndrome (15%), and Bickerstaff brainstem encephalitis (12%). External ophthalmoplegia (48%), sensory disturbance (9%), and bulbar palsy (9%) were the three most frequent onset symptom manifestations. Brain or spinal lesions on MRI and abnormal recordings by nerve conduction study were present in 18% (12/68) and 60% (27/45) of cases, respectively. There was CSF albuminocytologic dissociation in 34% of the patients (23/68). IV immunoglobulin alone or combined with steroids or plasma exchange was administered to 58% of patients (42/72). We did not find a significant correlation between early improvement up to 3 months and age onset and phenotype. All patients showed different degrees of recovery, and 81% (57/70) had complete recovery within 1 year. Conclusions: Acute ophthalmoparesis and classic Miller Fisher syndrome are the most common phenotypes of anti-GQ1b antibody syndrome in childhood. The majority of patients show good response to immunotherapy and have favorable prognosis.

Keywords: Guillain-Barré syndrome; Miller Fisher syndrome; anti-GQ1b antibody; diangnosis; immunotherapy; pediatric.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Algorithm of systematic review.
Figure 2
Figure 2
The onset symptoms and phenotypes of this cohort. (A) Phenotypes of anti-GQ1b antibody syndrome; (B) Subtypes categorized by age; (C) Onset symptoms of anti-GQ1b antibody syndrome in childhood; (D) Onset symptoms categorized by age. AAH, acute ataxic hypersomnolence; AAN, acute ataxic neuropathy; AC, altered consciousness; AO, acute ophthalmoparesis; AP, acute ptosis; APW, acute pharyngeal weakness; BBE, Bickerstaff brainstem encephalitis; BP, bulbar palsy; BWP, bifacial weakness with paraesthesias; EO, external ophthalmoplegia; FP, facial paralysis; GBS, Guillain-Barré syndrome; IO, internal ophthalmoplegia; LW, limb weakness; MFS, Miller Fisher syndrome; NA, not available; PCBW, pharyngeal-cervical-brachial weakness; PGBS, paraparetic GBS; SD, sensory disturbance.
Figure 3
Figure 3
Correlation between ACD and NCS. Ab, anti-GQ1b antibodies; ACD, albuminocytologic dissociation; NCS, nerve conduction study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1B is a possible marker of Miller Fisher syndrome. Ann Neurol. (1992) 31:677–9. 10.1002/ana.410310619 - DOI - PubMed
    1. Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry. (2013) 84:576–83. 10.1136/jnnp-2012-302824 - DOI - PubMed
    1. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry. (2001) 70:50–5. 10.1136/jnnp.70.1.50 - DOI - PMC - PubMed
    1. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. (1993) 43:1911–7. 10.1212/WNL.43.10.1911 - DOI - PubMed
    1. Yuki N, Susuki K, Hirata K. Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: relation to Miller Fisher syndrome. Neurology. (2000) 54:1851–3. 10.1212/WNL.54.9.1851 - DOI - PubMed

LinkOut - more resources